Pancreatic cancer, or Pancreatic Adenocarcinoma (PDAC) development can take up to 20 years until it reaches a metastatic, incurable stage. Unfortunately however, over 90% of all PDAC cases are diagnosed at this stage.

 

By fusing innovative big data 'omics' with our next-gen biomarker discovery platform, BiomaRx has built a proprietary systems biology engine to identify clinically relevant biomarkers.

Our primary is to develop a next generation, non-invasive and robust liquid biopsy diagnostic for early detection of pancreatic cancer, offering a dramatic improvement to the current state of treatment, and most importantly, to patients' lives.

 

Our Discoveries

  • The discovery and verification of a 5-gene classifier for early detection and surveillance of pancreatic cancer

  • This panel distinguishes pancreatitis, IPMN (early stage of pancreatic cancer), and malignant pancreatic cysts from normal pancreas and pancreatic cancer

  • The discovery and verification of protein liquid biopsy biomarkers for enhanced diagnostic accuracy

  • These protein biomarkers discriminate pancreatic cancer vs. healthy individuals and discriminate early from late stage pancreatic cancer

About BiomaRx

Based out of Cambridge, MA, BiomaRx is a seed-stage venture focused on making pancreatic cancer a treatable condition through early diagnosis. The team is developing a non-invasive diagnostic for pancreatic cancer, a disease that is projected to be the second leading cancer killer by 2020.

Spun out of Harvard Medical School and Beth Israel Deaconess Medical Center, BiomaRx uses a proprietary systems biology engine to identify next-gen diagnostic biomarkers and therapeutic targets for first-in class pancreatic cancer diagnosis and treatment.